Merck boosts oncology pipeline with $1bn deal

Merck has announced plans to acquire Peloton Therapeutics, a clinical-stage biopharmaceutical company, in a $1.05 billion bid to boost its oncology pipeline.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Americas

Merck to buy immunotherapy company for $300m

26 February 2019 US-based Merck & Co has announced plans to acquire immunotherapy company Immune Design for $300 million, in a bid to strengthen its capabilities in vaccine development.

Americas

Merck strengthens immunotherapy expertise with $773m buy

11 June 2019 US-based Merck & Co has announced plans to buy Tilos Therapeutics, its latest acquisition in the immunotherapy space.

Big Pharma

Fed Circuit sides with Merck in antifungal treatment dispute

25 June 2019 A US court has upheld a decision that eight claims of one of Mayne Pharma’s patents are unpatentable for obviousness over prior art after a validity challenge was brought by a subsidiary of Merck & Co.

More on this story

Americas

Merck to buy immunotherapy company for $300m

26 February 2019 US-based Merck & Co has announced plans to acquire immunotherapy company Immune Design for $300 million, in a bid to strengthen its capabilities in vaccine development.

Americas

Merck strengthens immunotherapy expertise with $773m buy

11 June 2019 US-based Merck & Co has announced plans to buy Tilos Therapeutics, its latest acquisition in the immunotherapy space.

Big Pharma

Fed Circuit sides with Merck in antifungal treatment dispute

More on this story

Americas

Merck to buy immunotherapy company for $300m

26 February 2019 US-based Merck & Co has announced plans to acquire immunotherapy company Immune Design for $300 million, in a bid to strengthen its capabilities in vaccine development.

Americas

Merck strengthens immunotherapy expertise with $773m buy

11 June 2019 US-based Merck & Co has announced plans to buy Tilos Therapeutics, its latest acquisition in the immunotherapy space.

Big Pharma

Fed Circuit sides with Merck in antifungal treatment dispute